E-resources
-
Groot, Vincent P; Mosier, Stacy; Javed, Ammar A; Teinor, Jonathan A; Gemenetzis, Georgios; Ding, Ding; Haley, Lisa M; Yu, Jun; Burkhart, Richard A; Hasanain, Alina; Debeljak, Marija; Kamiyama, Hirohiko; Narang, Amol; Laheru, Daniel A; Zheng, Lei; Lin, Ming-Tseh; Gocke, Christopher D; Fishman, Elliot K; Hruban, Ralph H; Goggins, Michael G; Molenaar, I Quintus; Cameron, John L; Weiss, Matthew J; Velculescu, Victor E; He, Jin; Wolfgang, Christopher L; Eshleman, James R
Clinical cancer research, 08/2019, Volume: 25, Issue: 16Journal Article
In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology-certified clinical laboratory. Digital-droplet PCR was used to detect the major PDAC-associated somatic mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed. ctDNA was detected preoperatively in 29 (49%) patients and was an independent predictor of decreased recurrence-free survival (RFS) and overall survival (OS). Patients who had neoadjuvant chemotherapy were less likely to have preoperative ctDNA than were chemo-naïve patients (21% vs. 69%; < 0.001). ctDNA levels dropped significantly after tumor resection. Persistence of ctDNA in the immediate postoperative period was associated with a high rate of recurrence and poor median RFS (5 months). ctDNA detected during follow-up predicted clinical recurrence sensitivity 90% (95% confidence interval (CI), 74%-98%), specificity 88% (95% CI, 62%-98%) with a median lead time of 84 days (interquartile range, 25-146). Detection of ctDNA during postpancreatectomy follow-up was associated with a median OS of 17 months, while median OS was not yet reached at 30 months for patients without ctDNA ( = 0.011). Measurement of ctDNA in a CLIA laboratory setting can be used to predict recurrence and survival in patients with PDAC.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.